Publication:
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Simple item page
dc.contributor.authorGarcía-Pérez, Javier
dc.contributor.authorBorobia, Alberto M
dc.contributor.authorPerez-Olmeda, Mayte
dc.contributor.authorPortolés, Antonio
dc.contributor.authorCastaño, Luis
dc.contributor.authorCampins-Artí, Magdalena
dc.contributor.authorBertrán, María Jesús
dc.contributor.authorBermejo, Mercedes
dc.contributor.authorArribas, José Ramón
dc.contributor.authorLópez, Andrea
dc.contributor.authorAscaso-Del-Rio, Ana
dc.contributor.authorArana-Arri, Eunate
dc.contributor.authorFuentes Camps, Inmaculada
dc.contributor.authorVilella, Anna
dc.contributor.authorCascajero Díaz, Almudena
dc.contributor.authorGarcía-Morales, María Teresa
dc.contributor.authorCastillo de la Osa, María
dc.contributor.authorPérez Ingidua, Carla
dc.contributor.authorLora, David
dc.contributor.authorJiménez Santana, Paloma
dc.contributor.authorPino-Rosa, Silvia del
dc.contributor.authorGómez de la Cámara, Agustín
dc.contributor.authorde la Torre-Tarazona, Humberto Erick
dc.contributor.authorCalonge, Esther
dc.contributor.authorCruces Fernández, Raquel
dc.contributor.authorBelda-Iniesta, Cristobal
dc.contributor.authorAlcamí, José
dc.contributor.authorFrías, Jesús
dc.contributor.authorCarcas, Antonio J
dc.contributor.authorDíez-Fuertes, Francisco
dc.contributor.authorCombiVacS Study Group
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderPlan Nacional de I+D+i (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.date.accessioned2025-01-15T13:11:21Z
dc.date.available2025-01-15T13:11:21Z
dc.date.issued2024-09-20
dc.description.abstractCombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).
dc.description.peerreviewedSí
dc.description.sponsorshipFunded by Instituto de Salud Carlos III (ISCIII). A.M.B., A.J.C., J.O., and J.F. are members of the VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. J.O. is a member of the INsTRuCT (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies. This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to public health. The Spanish Clinical Trials Platform is a public network funded by the Instituto de Salud Carlos III (grant numbers PTC20/00018 and PT17/0017), the State Plan for Research, Development, and Innovation 2013–16, the State Plan for Scientific and Technical Research and Innovation 2017–20, and the Subdirectorate General for Evaluation and Promotion of Research, Instituto de Salud Carlos III, cofinanced with FEDER funds. CombiVacS was designed under the umbrella of the VACCELERATE project. VACCELERATE and INsTRuCT received funding from the EU’s Horizon 2020 Research and Innovation Programme (grant agreement numbers 101037867 and 860003). The Instituto de Salud Carlos III is the Spanish partner in the VACCELERATE project. This work is funded by Instituto de Salud Carlos III through grants PI19CIII/00004 and PI21CIII/00025, the COVID-19 FUND (grants COV20/00679 and COV20/00072) and CIBERINFEC, co-financed with FEDER funds.
dc.format.number9
dc.format.page110728
dc.format.volume27
dc.identifier.citationGarcía-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F; CombiVacS Study Group. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants. iScience. 2024 Aug 14;27(9):110728.
dc.identifier.doi10.1016/j.isci.2024.110728
dc.identifier.e-issn2589-0042
dc.identifier.journaliScience
dc.identifier.pubmedID39286494
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26028
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PTC20/00018
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PT17/0017
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/101037867
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/860003
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI19CIII/00004
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI21CIII/00025
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/COV20/00679
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/COV20/00072
dc.relation.publisherversionhttps://doi.org/10.1016/j.isci.2024.110728
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.repisalud.instituteIIS::IdiPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid)
dc.repisalud.instituteIIS::IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
dc.repisalud.instituteIIS::IIS Biocruces - Instituto de Investigación Sanitaria Biocruces Bizkaia (País Vasco)
dc.repisalud.instituteIIS::IR-HUVH - Instituto de Investigación Hospital Universitari Vall d’Hebron (Cataluña)
dc.repisalud.instituteIIS::i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectImmune response
dc.subjectImmunology
dc.titleImmunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicatione4416b9d-e4ad-48e5-a0b6-e760b90bf5c5
relation.isAuthorOfPublicationd01866d4-34ba-4cd6-b995-3c4199bf0c59
relation.isAuthorOfPublicationa391b61e-450a-44e5-bff8-96587441fd7b
relation.isAuthorOfPublication0054c742-0072-491b-9f65-05a4f4ddcd7b
relation.isAuthorOfPublicationc6e55324-9e73-4d41-a581-03e2c7a4dc21
relation.isAuthorOfPublication2d052ae1-90ae-4f00-baba-23df1e14359c
relation.isAuthorOfPublication10d17a1c-f34b-499f-afd9-7a18509b4be1
relation.isAuthorOfPublication596e4147-6554-4a46-b44f-ee859e2a2053
relation.isAuthorOfPublication5427ef71-65f2-46b8-a759-ce3ee260702b
relation.isAuthorOfPublication9803e9de-d734-422a-acaf-fd345213fcfc
relation.isAuthorOfPublication1088c7fd-9ed9-463a-a84c-665b180650d5
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication05199c38-bb50-4a79-bb3b-96dce9769920
relation.isAuthorOfPublication05199c38-bb50-4a79-bb3b-96dce9769920
relation.isAuthorOfPublication.latestForDiscoverye4416b9d-e4ad-48e5-a0b6-e760b90bf5c5
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication0e5401ef-8ce7-439f-85e0-4e3550b5fade
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Immunogenicity_mRNA-vaccines_2024.pdf
Size:
3.49 MB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
Supplementary_Immunogenicity_mRNA-vaccines_2024.pdf
Size:
394.74 KB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Microbiología (CNM)
i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
IdiPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid)
IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
IIS BioBizkaia - Asociación Instituto de Investigación Sanitaria BioBizkaia (País Vasco)
IR-HUVH - Instituto de Investigación Hospital Universitari Vall d’Hebron (Cataluña)